Gene Editing of Checkpoint Molecules in Cord Blood-Derived Dendritic Cells and CD8 T Cells Using CRISPR-Cas9.

Immunotherapies targeting checkpoint inhibition and cell therapies are considered breakthroughs for cancer therapy. However, only a part of patients benefit from these treatments and resistance has been observed. Combining both approaches can potentially further enhance their efficacy.